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Abstract
Background: In this study, we used a systematic bioinformatics analysis approach to elucidate genes that exhibit
an endothelial cell (EC) restricted expression pattern, and began to define their regulation, tissue distribution, and
potential biological role.
Results: Using a high throughput microarray platform, a primary set of 1,191 transcripts that are enriched in
different primary ECs compared to non-ECs was identified (LCB >3, FDR <2%). Further refinement of this initial
subset of transcripts, using published data, yielded 152 transcripts (representing 109 genes) with different degrees
of EC-specificity. Several interesting patterns emerged among these genes: some were expressed in all ECs and
several were restricted to microvascular ECs. Pathway analysis and gene ontology demonstrated that several of the
identified genes are known to be involved in vasculature development, angiogenesis, and endothelial function
(P < 0.01). These genes are enriched in cardiovascular diseases, hemorrhage and ischemia gene sets (P < 0.001).
Most of the identified genes are ubiquitously expressed in many different tissues. Analysis of the proximal
promoter revealed the enrichment of conserved binding sites for 26 different transcription factors and analysis of
the untranslated regions suggests that a subset of the EC-restricted genes are targets of 15 microRNAs. While
many of the identified genes are known for their regulatory role in ECs, we have also identified several novel EC-
restricted genes, the function of which have yet to be fully defined.
Conclusion: The study provides an initial catalogue of EC-restricted genes most of which are ubiquitously
expressed in different endothelial cells.
Background
The endothelium, which lines the inner surface of all
blood vessels, participates in several normal physiologi-
cal functions including control of vasomotor tone, the
maintenance of blood fluidity, regulation of permeability,
formation of new blood vessels, and trafficking of cells
[1]. The endothelium also plays an important role in
several human diseases. In the setting of inflammation
several genes become activated within the endothelium
to facilitate the recruitment, attachment, and transmi-
gration of inflammatory cells. Over time, however, in
chronic inflammatory diseases EC responses become
impaired, leading to EC dysfunction.
As a cell type, ECs exhibit tremendous heterogeneity
[2]. For example, there are significant differences in EC
structure and function based on the size and type of
blood vessel, from larger arteries or veins, to medium
sized arterioles or venules, down to capillary ECs. There
is also significant heterogeneity at the level of a particu-
lar tissue or organ. For example, in the brain, the
endothelium plays a particularly important protective
role as part of the blood brain barrier with ECs that are
closely attached to one another forming a tight barrier
that is impermeable to the passage of even small solutes
or ions. In contrast, in the liver, the sinusoidal ECs are
fenestrated so that small to moderate size transcellular
pores promote the uptake of large lipid containing parti-
cles from the blood [3,4].
The endothelium is known to play an important role
in several human diseases including atherosclerosis, dia-
betes mellitus, and sepsis. The overall goal of the cur-
rent study was to use primary and publicly available
microarray data from human ECs, non ECs, and tissues,
to identify genes that exhibit an EC-restricted pattern,
define their distribution in different tissues, and
* Correspondence: joettgen@bidmc.harvard.edu
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston MA 02215, USA
Bhasin et al. BMC Genomics 2010, 11:342
http://www.biomedcentral.com/1471-2164/11/342
© 2010 Bhasin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.determine whether changes in the expression of any of
the genes are linked to particular diseases. Our study,
has for the first time, identified and ranked a significant
number of genes that exhibit an EC-restricted expres-
sion pattern. Among these genes, several interesting pat-
terns of expression emerge. Whereas many of the genes
are expressed in all ECs, some are restricted to micro-
vascular ECs. The vast majority of EC-restricted genes
a r ee x p r e s s e di nm u l t i p l et i ssues. The EC-restricted
genes were found to be associated with a number of dif-
ferent cellular functions including vasculature develop-
ment, cell differentiation, and angiogenesis. Analysis of
the regulatory regions of the EC-restricted genes
demonstrated enrichment of binding sites for a selected
number of transcription factors and microRNAs.
Methods
Cell culture
HUVEC (human umbilical vein EC cell; Lonza), HAEC
(human aortic EC cells), HCAEC (human coronary artery
EC cells), HPAEC (human pulmonary artery EC cells),
and HMVEC (human microvascular (dermal) EC cell;
kindly provided by Dr. William Aird) were grown in
EBM-2 (EC Cell Basal Medium-2) supplemented with
EGM SingleQuots (Lonza). HASMC (human aortic
smooth muscle cell) were grown in SmBM Basal Medium
supplemented with SmGM-2 SingleQuot (Lonza). For the
isolation of the T and B cells, discarded leukocytes from
platelet donations by healthy human donors were used in
this study. Samples were obtained from subjects after
informed consent was obtained using an institutionally
approved protocol (IRB protocol 2005-P-001364/2). Red
blood cells were removed using Ficoll-Paque PLUS
according to manufacturer’s protocol. (GE-Healthcare.
Uppsala Sweden). Donor Peripheral Blood Mononuclear
Cells (PBMC) were stained with pan T-cell specific CD3-
PE and pan B-cell specific CD20-FITC antibodies. Fluor-
escently labeled cells were sorted using a high speed cell
sorter. (FACS Aria. BD biosciences San Jose. California).
RNA isolation
Total RNA was isolated using the RNAeasy kit (QIA-
GEN) following the manufacturer’s instructions.
Microarray Analysis
Transcriptional profiling of endothelial and non-EC cells
was performed using the Affymetrix oligonucleotide
microarray HT U133 plate with 24 chips according to a
standard Affymetrix protocol for cDNA synthesis, in
vitro transcription, production of biotin-labeled cRNA,
hybridization of cRNA with HT Plate A and B, and
scanning of image output files [5]. The quality of hybri-
dized chips was assessed using Affymetrix guidelines on
the basis of average background, scaling factor, number
of genes called present, 3’ to 5’ ratios for beta-actin and
GAPDH and values for spike-in control transcripts [6].
We also checked for reproducibility of the samples by
using chip to chip correlation and signal-to-noise ratio
(SNR) methods for replicate arrays. All the high quality
arrays were included for low and high level bioinfor-
matics analysis. Primary gene expression data are pub-
licly available at GEO http://www.ncbi.nlm.nih.gov/geo/
in GSE21212.
Statistical Analysis
To obtain the signal values, high quality chips were
further analyzed by dChip, as it is more robust than
MAS5.0 and RMA in signal calculation. The raw probe
level data was normalized using smoothing-spline invar-
iant set method. The signal value for each transcript
was summarized using PM-only based signal modeling
algorithm described in dChip. The PM only based mod-
eling based algorithm yields less number of false posi-
t i v e sa sc o m p a r e dt ot h eP M - M Mm o d e l .I nt h i sw a y ,
the signal value corresponds to the absolute level of
expression of a transcript[7]. These normalized and
modeled signal values for each transcript were used for
further high level bioinformatics analysis. During the
calculation of model based expression signal values,
array and probe outliers are interrogated and image
spikes are treated as signal outliers.
When comparing two groups of samples to identify
genes enriched in a given phenotype, if the 90% lower
confidence bound (LCB) of the fold change (FC)
between the two groups was above 3 and median false
discovery rate is <2%, the corresponding gene was con-
sidered to be differentially expressed [8]. LCB is a strin-
gent estimate of FC and has been shown to be the
better ranking statistic [9]. It has been suggested that a
criterion of selecting genes that have an LCB above 2.0
most likely corresponds to genes with an “actual” fold
change of at least 3 in gene expression [8,10].
Identification of EC-restricted genes
The list of differentially expressed genes obtained from
the primary analysis (previous section) was further ana-
lyzed through a series of steps to obtain EC-restricted
genes. This analysis was performed using the following
three steps, i); determination of the enrichment score,
ii); performing an outlier analysis, and iii); ranking the
genes according to EC specificity.
i) Enrichment Score [ECS]
The enrichment analysis was performed to determine
the probability that genes are specifically over expressed
in ECs as compared to other primary non-ECs. For this
analysis we used the public REFEXA database http://
www.lsbm.org/site_e/database/index.html. The REFEXA
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of primary cells, cancer cell lines, and tissues. The
MAS5 normalized data was manually obtained from the
database for all the transcripts that were identified as
highly expressed in ECs compared to non-ECs in the
primary analysis. The enrichment score of each gene
was determined by calculating the relative expression in
the ECs compared to non-ECs. Each transcript was
assigned a present/absent call in every primary cell on
the basis of expression value. The transcript is called
present (P) in a primary non-endothelial cell if it was
expressed >50% of the expression level in the primary
ECs, otherwise it was called absent (A). The EC score
(ECS) is obtained using the following equation:
ECSj =+
= ∑ Ai Pi Ai
i
n
/( )
0
(1)
where ECSj is the enrichment score for a transcript j,
Ai and Pi are the present and absent calls for the tran-
script in different normal primary cells (n).
ii) Outlier Analysis
The outlier analysis was performed on the list of genes
obtained after step i) for the selection of genes with
restricted EC expression. The outlier analysis was per-
formed by means and standard deviation of the expres-
sion values using publicly available microarray data. If
t h ee x p r e s s i o no fag i v e nt r a nscript in a sample falls 2
standard deviations outside of the mean expression in
the distribution obtained using all samples, the particular
sample is considered as an outlier. If the cluster of the
outliers consists only of ECs, the genes were considered
as good candidates for being EC-restricted. On the con-
trary, if the cluster of the outliers consists of ECs and
non-ECs, these genes were considered to have less speci-
ficity for ECs and were filtered out from the final analysis.
iii) Ranking of EC-restricted genes
After the outlier and enrichment analysis, all the identi-
fied EC-restricted genes were ranked on the basis of
average fold change of a gene in ECs as compared to
non ECs (REF_FOLD) in publicly available datasets
(REFEXA) and Fold change between ECs and non-ECs
from our primary experiment (FC) [EQ 2]. The genes
with high REF_FOLD and high FC are considered to be
more EC-restricted and assigned a higher rank.
Rank REF FOLD  FC ii i =× _ (2)
where REF_FOLD = (Expression in ECs in public set/
Expression in Non-EC) and FC = (Expression in ECs in
primary set/Expression in Non-EC).
To further reduce the false positive rate, we have
selected the top 60% of the transcripts with greater than
3f o l de x p r e s s i o ni nE C sc o m p a r e dt on o n - E C sa sg o o d
candidates for endothelial restriction.
Pathways, Gene ontology and Disease set enrichment
analysis of EC-restricted genes
The functional analysis of the EC-restricted genes was
performed in terms of canonical pathways, disease sets
and gene ontology (GO) categories. The canonical path-
ways and disease set enrichment analysis was performed
using the MetaCore tool of GeneGo package http://
www.genego.com/. It consists of manually curated infor-
mation about gene regulation, protein interactions, and
metabolic and signaling pathways. The overrepresented
canonical pathways and disease biomarker sets were
ranked on the basis of P values obtained using the
Simes procedure accounting for multiple hypothesis
testing representing the probability of mapping arising
by chance, based on the number of EC-restricted genes
identified in a particular canonical pathway or disease
compared to the total number of genes in the GO cate-
gory/Disease set. The Go categories/Disease set with a
False Discovery Rate (FDR) corrected P value <0.05
were considered significant.
The Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) was used to identify over-
represented gene ontology categories form the
endothelial restricted genes [11]. DAVID is an online
implementation of the EASE software that produces the
list of overrepresented categories using jackknife itera-
tive resampling of the Fisher exact probabilities. A score
was assigned to each category by using “-log” of EASE
score to show the significantly enriched gene ontology
categories. The related gene ontology categories were
merged into a cluster using the functional clustering
module of DAVID. Higher enrichment scores for parti-
cular genes reflect increasing confidence in their over-
representation.
Analysis of transcription factor binding sites
Recent improvements in bioinformatics methods for
the analysis of sequences regulating transcription have
made it possible to elucidate potential factors involved
in regulating key regulatory networks underlying a
transcriptional response. We divided the EC specific
genes into two sets on the basis of K Mean clustering
for promoter analysis i) high expression in all ECs ii)
and high expression in HMVEC. The promoter analy-
sis was performed separately on these two sets using
the online tool ExPlain http://explain.biobase-interna-
tional.com/cgi-bin/biobase/ExPlain_2.4.2/ for detection
of over-represented transcription factor binding sites.
ExPlain uses the MatchTM, a weight matrix-based tool
for searching putative transcription factor binding sites
[12,13].
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upstream to 100 bp downstream of the transcription
start site of each gene (Yes set). The enrichment was
obtained against a random set of promoters obtained
from human housekeeping genes (No set). The entire
vertebrate non-redundant set of transcription factors
matrix from transfac database was used for scanning
potential binding sites [14]. The matrices that did not
differ much in density between the positive and negative
set were removed from the results. A significant over-
representation of a transcription factor binding site in a
target set as compared to the background set was deter-
mined using a 1-tailed Fisher exact probability test [P
value < 0.01,FC (yes_set/no_set) > 1.2). After completion
of the enrichment analysis, the transcription factor bind-
ing sites for each set were compared with each other, in
order to identify TF binding sites that were common
and distinct among the different types of ECs (e.g. all,
microvascular).
MicroRNA target analysis
Another potential mechanism of regulating EC specific
genes could be through miRNA, a class of small non-
coding RNAs, that regulate gene expression primarily
through post-transcriptional repression by promoting
mRNA degradation in a sequence-specific manner [15].
We were interested in identifying whether miRNA bind-
ing sites are enriched in EC-restricted genes. Computa-
tional analysis of the miRNA targets sites was
performed using Composite Regulatory Signature Data-
base (CRSD) http://140.120.213.10:8080/crsd/main/
home.jsp, a comprehensive server for composite regula-
tory signature discovery. CRSD has a package for pre-
diction of miRNA binding sites by searching the UTRs
for segments of perfect Watson-Crick in the 3’UTR of
the target gene set [16].The miRNA binding sites for
each of the micro RNA are calculated in the EC-
restricted set and the background set (54,576 genes
from human unigenes). The enrichment of each miRNA
binding site is calculated on the basis of its abundance
in the EC-restricted set and the background set. The
significance of enrichment is expressed as a P value
(smaller the P value more significant is the enrichment).
Tissue specificity of EC specific Gene
In order to determine the normal tissue distribution of
the EC specific genes, we obtained the normalized
expression level from the Stanford Source database [17].
Source database presents the relative expression level of a
gene in different tissues that is normalized for the num-
ber of samples from each tissue included in UniGene.
T h eg e n ee x p r e s s i o ni n f o r m a t i o nf o rt h ed i f f e r e n tt r a n -
scripts was obtained from dbEST expression profile.
In addition to relative gene expression information
from the Source database, we have also manually
curated the protein expression information about the
endothelial specific genes from the Human Protein
Atlas database. The Human Protein Atlas is a compre-
h e n s i v ed a t a b a s et h a tp r o v i des the protein expression
profiles for a large number of human proteins, pre-
sented as immunohistological images from most human
tissues [18,19]. It contains antibody-based protein
expression and localization profiles of >4,000 proteins in
48 normal human tissues and 20 different cancers [20].
The expression level of each protein is presented in a
four color scale system that takes into consideration the
intensity of the protein expression and quantity of posi-
tive images tested for each protein. It is a very useful
tool to extract the relative expression level of proteins in
different tissues.
Quantitative real-time PCR
Total RNA was isolated using the RNAeasy kit
(QIAGEN, Valencia, CA). Single stranded cDNA was
synthesized from total RNA using High Capacity RNA-
to-DNA Kit (Applied Biosystems). SYBR Green I-based
real-time PCR was carried out on an Opticon Monitor.
The sequences of the primers used in this study are
listed in Additional File 1. For normalization of each
sample, human specific TATA-binding protein (TBP)
primers were used to measure the amount of TBP
cDNA.
Results
Identification of EC-restricted genes
In an effort to identify genes that exhibit an EC-
restricted pattern total RNA was isolated from primary
cultured ECs (including HUVEC, HPAEC, HAEC,
HMVEC, and HCAEC) and non-ECs (HASMC, B cells,
T cells). Gene expression profiling was performed using
a high throughput platform, HT U133 plate, that mea-
sures more than 43,000 well-characterized genes and
UniGene clusters. The expression profiling was per-
formed in duplicate. All the array data was determined
to be of high quality as assessed by the scaling factor,
average background, percent present calls, and 3’/5’RNA
ratio. After normalization and preprocessing of the data,
we generated a list of genes that are significantly differ-
entially expressed between different ECs and non-ECs.
The heterogeneity in the transcription profile of the EC
was identified using unsupervised clustering, reflecting
the global similarities between the samples [Figure 1A].
Unsupervised clustering demonstrated the highest simi-
larity within the biological replicates and the least simi-
larity between ECs and non-ECs. The cladogram
produced by unsupervised clustering depicted that
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expression profile as compared to microvascular cells.
Comparing groups, we found 1,713 transcripts that are
differentially expressed in HMVEC compared to non-
ECs (LCB > 3 and FDR < 2%). Similarly for HUVEC
and HPVEC, 1,534 and 1,539 transcripts were respec-
tively differentially expressed compared to non-ECs. For
the arterial EC cells, 1,239 HCAEC and 1,316 HAEC
transcripts were determined to be differentially
expressed in these cells compared to non-ECs. Compari-
son of the differentially expressed transcripts in micro-
vascular (HMVEC), venous (HUVEC, HPVEC) and
arterial (HAEC, and HCAEC) cells using Venn diagrams
revealed that approximately half of the transcripts are
differentially expressed in all three EC types. However
we also observed that each EC type possessed a unique
expression signature; the differential expression of tran-
scripts was limited to one type of EC [Figure 1B].
Figure 1 Overall approach for extraction of endothelial restricted genes. A) Unsupervised Pearson Correlation based cluster of different EC
and non-EC arrays after normalizing the data. ECs (HMVEC, HUVEC, HPVEC, HAEC, and HCEAC) form separate clusters from non-ECs (HSAMC, B
Cells, T Cells). In most of cases biological replicates of each cell type have better correlation with each other than with other cell types. B) Venn
diagram indicating overlap between microvascular, arterial and venous endothelial differentially expressed genes obtained from the primary
analysis C) Schematic representation of the approach for identifying the genes with EC-restricted expression (EC-restricted) D) Venn diagram
depicting the overlap between microvascular, arterial and venous endothelial restricted transcripts.
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Probe Gene Symbol UGCluster FC REFEXA_FC Rank
205612_at MMRN1 Hs.268107 172.65 64.625 11157.50625
204482_at CLDN5 Hs.505337 124.75 47.5625 5933.421875
202112_at VWF Hs.440848 61.15 78.05172414 4772.862931
206464_at BMX Hs.495731 55.28 80.46153846 4447.913846
205572_at ANGPT2 Hs.583870 69.88 20.21875 1412.88625
204904_at GJA4 Hs.296310 37.23 34.5 1284.435
204677_at CDH5 Hs.76206 79.89 13.96610169 1115.751864
204468_s_at TIE1 Hs.78824 78 14.19626168 1107.308411
226028_at ROBO4 Hs.524121 34.97 27.89130435 975.358913
227779_at ECSCR Hs.483538 53.73 12.03448276 646.6127586
222856_at APLN Hs.303084 76.9 8.106666667 623.4026667
207526_s_at IL1RL1 Hs.66 64.53 9.56846473 617.453029
204134_at PDE2A Hs.503163 43.51 13.72368421 597.1175
214319_at FRY Hs.507669 38.96 15.2962963 595.9437037
219059_s_at LYVE1 Hs.655332 88.96 6.384615385 567.9753846
201785_at RNASE1 Hs.78224 28.82 18.38461538 529.8446154
236262_at MMRN2 Hs.524479 28.44 18.28571429 520.0457143
204818_at HSD17B2 Hs.162795 133.64 3.846938776 514.104898
220637_at FAM124B Hs.147585 17.93 23.09090909 414.02
229902_at FLT4 Hs.646917 19.45 20.94594595 407.3986486
205392_s_at CCL14 Hs.714858 45.05 8.48 382.024
223567_at SEMA6B Hs.465642 17.28 21.82608696 377.1547826
211273_s_at TBX1 Hs.173984 35.43 10.18181818 360.7418182
213715_s_at KANK3 Hs.322473 34.78 10.23076923 355.8261538
222885_at EMCN Hs.152913 36.24 8.930555556 323.6433333
206331_at CALCRL Hs.470882 44.19 7 309.33
225369_at ESAM Hs.173840 14.83 20.10714286 298.1889286
219837_s_at CYTL1 Hs.13872 47.07 5.946969697 279.9238636
241926_s_at ERG Hs.473819 79.8 3.44 274.512
238488_at LRRC70 Hs.482269 12.1 21 254.1
203934_at KDR Hs.479756 40.75 6.224137931 253.6336207
227923_at SHANK3 Hs.149035 15.6 12.96296296 202.2222222
225817_at CGNL1 Hs.148989 27.25 7.260869565 197.8586957
229002_at FAM69B Hs.495480 26.39 7.414634146 195.6721951
228489_at TM4SF18 Hs.22026 53.73 3.328 178.81344
210082_at ABCA4 Hs.416707 16.65 9.857142857 164.1214286
235334_at ST6GALNAC3 Hs.337040 24.36 6.659090909 162.2154545
229309_at ADRB1 Hs.99913 19.91 7.891891892 157.1275676
235044_at CYYR1 Hs.37445 23.53 5.6 131.768
205569_at LAMP3 Hs.518448 14.72 8.56 126.0032
229233_at NRG3 Hs.125119 19.5 6.285714286 122.5714286
235050_at SLC2A12 Hs.486508 17.4 6.363636364 110.7272727
220027_s_at RASIP1 Hs.233955 16.99 6.03125 102.4709375
204683_at ICAM2 Hs.431460 9.09 11.23245614 102.1030263
220300_at RGS3 Hs.494875 29.92 3.411764706 102.08
206283_s_at TAL1 Hs.705618 24.65 4.097222222 100.9965278
227307_at TSPAN18 Hs.385634 7.32 13.53333333 99.064
206210_s_at CETP Hs.89538 7.91 12.33333333 97.55666667
228601_at LOC401022 Hs.98661 12.94 7.36 95.2384
218825_at EGFL7 Hs.91481 13.85 6.789473684 94.03421053
211518_s_at BMP4 Hs.68879 28.88 3.243243243 93.66486486
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229726_at GRAP Hs.567416 9.1 10.14285714 92.3
229376_at PROX1 Hs.585369 26.82 3.338461538 89.53753846
204368_at SLCO2A1 Hs.518270 17.02 5.051724138 85.98034483
230132_at ATP5SL Hs.351099 22.49 3.585106383 80.62904255
209543_s_at CD34 Hs.374990 17.19 4.68115942 80.46913043
228311_at BCL6B Hs.22575 12.6 6.333333333 79.8
219568_x_at SOX18 Hs.8619 3.72 21.42857143 79.71428571
218736_s_at PALMD Hs.483993 17.5 4.270072993 74.72627737
204681_s_at RAPGEF5 Hs.174768 22.02 3.351851852 73.80777778
239665_at LOC441179 Hs.719702 20.51 3.578947368 73.40421053
238846_at TNFRSF11A Hs.204044 11.24 6.416666667 72.12333333
222911_s_at CXorf36 Hs.98321 18.06 3.953703704 71.40388889
231887_s_at KIAA1274 Hs.202351 13.86 4.685185185 64.93666667
202411_at IFI27 Hs.532634 8.4 7.202764977 60.50322581
205581_s_at NOS3 Hs.647092 11.89 4.958333333 58.95458333
206481_s_at LDB2 Hs.714330 18.81 3.117505995 58.64028777
224385_s_at MOV10L1 Hs.62880 5.37 10.09090909 54.18818182
230250_at PTPRB Hs.434375 13.61 3.787878788 51.5530303
230673_at PKHD1L1 Hs.170128 4.04 12.625 51.005
222908_at FAM38B Hs.585839 7.79 6.5 50.635
240646_at GIMAP8 Hs.647121 8.59 5.7 48.963
231792_at MYLK2 Hs.86092 13.89 3.5 48.615
208983_s_at PECAM1 Hs.514412 9.63 4.606138107 44.35710997
51158_at FAM174B Hs.27373 12.38 3.533333333 43.74266667
214156_at MYRIP Hs.594535 3.08 12.88888889 39.69777778
205507_at ARHGEF15 Hs.443109 11.7 3.202898551 37.47391304
218901_at PLSCR4 Hs.477869 7.29 5.044217687 36.77234694
228342_s_at ALPK3 Hs.459183 12.23 3 36.69
219247_s_at ZDHHC14 Hs.187459 4.32 8.176470588 35.32235294
213552_at GLCE Hs.183006 10.2 3.446428571 35.15357143
205247_at NOTCH4 Hs.436100 6.44 5.409090909 34.83454545
205003_at DOCK4 Hs.654652 11.06 3.085365854 34.12414634
218711_s_at SDPR Hs.26530 8.83 3.822222222 33.75022222
201801_s_at SLC29A1 Hs.25450 10.62 3.057324841 32.46878981
218995_s_at EDN1 Hs.511899 9.37 3.31779661 31.08775424
206855_s_at HYAL2 Hs.76873 5.2 5.645502646 29.35661376
226636_at PLD1 Hs.382865 8.18 3.347826087 27.38521739
211177_s_at TXNRD2 Hs.443430 6.85 3.825688073 26.2059633
228245_s_at OVOS Hs.524331 6.8 3.851485149 26.19009901
218805_at GIMAP5 Hs.647079 4.08 6.153846154 25.10769231
233924_s_at EXOC6 Hs.655657 6.79 3.680672269 24.99176471
223796_at CNTNAP3 Hs.658328 7.27 3.396039604 24.68920792
220945_x_at MANSC1 Hs.591145 8.04 3.065934066 24.65010989
230800_at ADCY4 Hs.443428 7.13 3.260869565 23.25
237466_s_at HHIP Hs.507991 5.84 3.927492447 22.93655589
205635_at KALRN Hs.8004 4.8 4.657894737 22.35789474
240890_at LOC643733 Hs.713751 3.71 5.5 20.405
213030_s_at PLXNA2 Hs.497626 5.18 3.504761905 18.15466667
243337_at FREM3 Hs.252714 3.42 4.461538462 15.25846154
226882_x_at WDR4 Hs.248815 3.51 4.122807018 14.47105263
232080_at HECW2 Hs.654742 4.02 3.578947368 14.38736842
210044_s_at LYL1 Hs.46446 4.42 3.239669421 14.31933884
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Page 7 of 18The total number of transcripts that are significantly
different in at least one of the EC types compared to
non-ECs consists of 2553, representing 1617 genes. To
further refine our initial list of EC-restricted genes, we
evaluated the expression of these genes using the data
from REFEXA http://www.lsbm.org/site_e/database/
index.html to identify EC-restricted genes. To calculate
an enrichment score for each gene, expression values
were manually obtained for each transcript using the
REFEXA database http://www.lsbm.org/site_e/database/
index.html. This database has MAS5 normalized gene
expression data for several primary cells, including ECs,
cancer cell lines, and normal tissues. For analysis we only
used the expression data for 30 primary cells and
excluded all cancer cell lines. The enrichment and outlier
analysis identified 289 outlier transcripts with an enrich-
ment score of 1 (see methods for details). To further
reduce the number of false positive results, the top 60%
(168 transcripts) of transcripts with an average of greater
than or equal to 3 fold overexpression in EC cells as
compared to non-EC cells were considered EC-restricted.
The expression value of these 168 transcripts was manu-
ally checked and transcripts with reduced specificity were
removed. After manual inspection of relative expression
profiles of each transcript, we selected 152 transcripts
that correspond to 109 valid genes exhibiting an EC-
restricted pattern (Table 1). The 152 transcripts with
varying EC specificity are ranked on the basis of fold
change in the primary set and fold change from the
external datasets (e.g. REFEXA). The Rank score is a sig-
nificance level with larger rank scores indicating increas-
ing confidence in endothelial restriction. The overall
schema of curating endothelial specific genes is shown in
Figure 1C. Many genes that are known to be EC-
restricted, including angiopoietin-2, von Willebrand’s fac-
tor (vWF), VE-cadherin (CD144) are at the top of the list
(Table 1). Comparison of the EC-restricted transcripts in
microvascular (HMVEC), venous (HUVEC, HPVEC) and
arterial (HAEC, and HCAEC) cells using Venn diagrams
revealed that most of the transcripts are differentially
expressed in all three EC cell types. Only a small fraction
of transcripts are uniquely differentially expressed in
microvascular ECs [Figure 1D]. A colorogram demon-
strating the expression pattern for each of the EC-
restricted genes is shown in Figure 2. The colorogram
consists of a range of patterns from transcripts highly
expressed in all EC types (Pattern IV) to transcripts that
are highly expressed in particular EC types (Pattern I).
ANGPT2, TBX1, FLT4 are examples of genes that are
highly expressed in the HMVEC cells. The expression
patterns of EC-restricted genes were further confirmed
using the REFEXA dataset [Figure 3]. To further validate
the microarrays results, we used PCR to quantitate the
expression levels of 12 randomly selected EC-restricted
genes in primary ECs and non-ECs. A very similar EC-
restricted expression pattern was observed for all 12
genes [Figure 4]. Although the relative fold enrichment
of some of the EC-restricted genes was somewhat lower
than initially identified by microarray analysis, the
expression in non-ECs remained quite low or absent in
comparison to ECs.
Pathways and Gene Ontology (GO) Processes modulated
by EC-restricted genes
We performed an enrichment analysis of the EC-
restricted genes to identify the pathways and GO pro-
cesses where the EC-restricted genes occur more often
than would be expected by random distribution. The
pathway enrichment analysis was performed using the
MetaCore tool of the GeneGO package where P values
of <0.05 (FDR adjusted) are considered significant. The
enrichment analysis identified a set of statistically signif-
icant enriched pathways (Figure 5A). The most highly
enriched pathways included “EC contacts by junctional/
nonjuctional mechanisms“, “Regulation of eNOS activity
in cardiomyocytes and endothelial cells“, “thrombospon-
din signaling“, “Role of PKA in cytoskeleton reorganiza-
tion“, many of which would be expected based on the
identified gene list. The enrichment analysis for GO
categories was performed using the Database for Anno-
tation, Visualization and Integrated Discovery (DAVID)
program. The top clusters of biological processes and
metabolic functions that are enriched in the set of dif-
ferentially expressed genes are shown in Figure 5B. The
most highly enriched clusters of the gene ontology cate-
gories included vasculature development and angiogen-
esis, immune responses, cell adhesion, and cell motility
and migration. Vascular development and angiogenesis
is the highest enriched GO cluster in which the EC-
restricted genes are overrepresented (Enrichment score
Table 1 List of the endothelial restricted genes with detailed annotation and rank score (Continued)
205680_at MMP10 Hs.2258 4.03 3.326693227 13.40657371
206222_at TNFRSF10C Hs.655801 3.29 3.714285714 12.22
219777_at GIMAP6 Hs.647105 3.64 3.335664336 12.14181818
203650_at PROCR Hs.647450 3.27 3.582278481 11.71405063
222446_s_at BACE2 Hs.529408 3.26 3.023094688 9.855288684
238036_at SHE Hs.591481 3.06 3.219512195 9.851707317
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Page 8 of 18Figure 2 Colorgram depicting the expression of EC-restricted genes in different cell types in the primary set. The columns represent the
samples and rows represent the genes. Gene expression is shown with a pseudocolor scale (-3 to 3) with red color denoting high expression
level and green color denoting low expression level of the gene. The scatter plots along the heatmap depict the different patterns in expression
of EC-restricted genes obtained using K mean clustering. The K mean clusters are represented as scatter plots with bars denoting the mean
expression level. Pattern I and IV depict a range of expression patterns exhibited by EC-restricted genes. For example pattern IV and I denotes
the genes that are highly expressed in all endothelial cell types (pan EC) and HMVEC cells respectively.
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Page 9 of 18Figure 3 Expression of ECs restricted genes in REFEXA database. A) Hierarchical clustering analysis of EC-restricted expression genes using
REFEXA gene expression data. The columns represent the samples (primary endothelial and non endothelial cells from REFEXA database) and
rows represent the genes. The detailed information about the primary cells can be obtained from REFEXA database http://157.82.78.238/refexa/
main_search.jsp. Gene expression is shown with pseudocolor scale (-3 to 3) with red denoting high expression level and green denoting low
expression level of gene.
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Page 10 of 184.72). This finding supports the overall concept that at
least a subset of the genes we identified as being EC-
restricted have previously been described in processes
known to involve ECs.
Disease set enrichment of EC-restricted genes
In order to evaluate whether the EC-restricted genes are
potentially linked to the pathogenesis of certain human
diseases, we performed a disease set enrichment analysis
using disease sets on the basis of published literature
(DSPL). DSPL enrichment analysis was performed using
the MetaCore tool in the GeneGO package. The disease
associations are summarized in Figure 5C, depicting the
top diseases in which EC-restricted are enriched. The
EC-restricted genes are enriched in the many cardiovas-
cular diseases including ventricular dysfunction, myocar-
dial infarction, hypertension, diabetic angiopathies,
arteriosclerosis, and several other vascular diseases.
Interestingly, ischemia was listed as a disease in which
the EC-restricted are over-represented (P value = 2E-
06). The EC-restricted genes are also enriched (P value
< 0.01) in neurological diseases including subarachnoid
hemorrhage (P value = 3.00E-07).
Regulatory mechanism governing EC-restricted genes
To begin to understand the complex and intricate regu-
lation of the EC-restricted genes, we were interested in
determining whether certain transcription factors or
miRNAs might be involved in regulating these genes.
Transcription factors play a critical role in defining cell
and tissue specificity of gene expression. In this study
the TFactor enrichment analysis was performed on two
sets of EC-restricted genes categorized on the basis of
expression profiles; the sets of genes are highly
expressed in i); all EC types (pan EC), ii); only in
HMVEC. The TFactor enrichment analysis was only
performed on these two sets as they constitute the
major fraction of EC-restricted genes. TFactor enrich-
ment analysis was performed using the ExPlain tool, a
program for gene expression analysis from BIOBASE.
We performed the analysis on a region 2 kb upstream
to 100 bp downstream of each of the EC-restricted
genes using vertebrate_non_redundant matrices (yes
set). Background frequencies were calculated based on
the promoters of human housekeeping genes (No set)
[12]. A TF binding site was considered to be enriched in
Figure 4 Validation of a selected subset of endothelial-restricted genes by quantitative RT-PCR. Validation of a subset of EC-restricted
genes from Table 1 was conducted using primary ECs and non-ECs by quantitative RT-PCR (n = 3 per cell type). The gene symbol is listed for
each gene. RQ refers to “relative quantity” where the expression in HUVECs has been set to 1.0 and the relative expression of the other cell
types are compared to that in HUVECs.
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Page 11 of 18Figure 5 Enrichment analysis of EC-restricted genes. A) Top enriched Canonical Pathways B) Top enriched GO Processes. C) Top enriched
disease set. The analysis for pathways and disease set enrichment was performed using the MetaCore tool of the GeneGo package. The GO
categories enrichment analysis was performed using the DAVID tool. The Bar graphs depict the enriched pathway or Go process categories and
-log of the P value. The P value depicts the significance of enrichment, the smaller is the P value the more significant is the enrichment. The
pathways and disease sets with FDR adjusted P value < 0.05 are considered significant. The panel for gene ontology enrichment depicts the
enrichments for each GO category (-log P value) as well as the Escore for a cluster of related GO categories.
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Page 12 of 18ag e n es e to nt h eb a s i so ft h ePv a l u e( Pv a l u e<0 . 0 0 1
and Yes/No > 1.2). The analysis identified binding sites
for >20 transcription factors, among the EC-restricted
genes expressed in all EC, and in the subset enriched
only in microvascular ECs [Figure 6]. Binding sites for
the TF factor that were identified for both of these sets
of genes included, CDXA,G A T A ,I P F 1 ,N F A T ,C D P ,
AIRE and OCT1. However, the binding sites for particu-
lar sets of transcription factors (e.g. FAC1, POU1F1,
STAT1, AR, SRF, LRH) are only enriched in promoters
of microvascular EC-restricted genes.
Another mechanism by which gene expression can be
regulated is through small noncoding RNAs or micro-
RNAs (miRNA). MiRNAs regulate gene expression
through translational repression of mRNA by promoting
the degradation of mRNA by binding to specific sequences
in the untranslated regions of the mRNA. We performed a
bioinformatics analysis of the EC-restricted genes in order
to identify whether the identified EC-restricted genes are
targets of miRNAs. We used composite regulatory signa-
ture database (CRSD) web tools that take into considera-
tion the sequence match and free energy of binding to
predict binding sites [16]. Our analysis identified 31
miRNA binding sites that are significantly enriched (P
value < 0.05) in the UTR of the EC-restricted genes [Fig-
ure 7]. Mir-432, Mir-188, and Mir-331 target each have
putative binding sites in the 3’ UTR of >8 EC-restricted
genes. A summary of the miRNA binding sites for EC-
restricted genes is provided in Table 2. Additionally details
of miRNA Binding sites along with target and reference
sequences are provided in Additional File 2.
Expression pattern of EC-restricted genes in tissues
A better understanding of how the EC-restricted genes
are expressed in different tissues can help to define their
function and potential use as disease biomarkers. Rela-
tive expression of the EC-restricted genes in several nor-
mal tissues was obtained using the Source databases
http://source.stanford.edu. In the source database the
normalized gene expression represents the relative
expression level of a gene in different tissues. The color-
ogram depicting the percentage of relative expression of
each gene is shown in Figure 8. The analysis demon-
strates that most of the endothelial restricted genes have
preferential expression in vascular tissues. In particular
MMRN1, BMX, ANGPT2 and CDH5 demonstrate high
expression levels in vascular tissues. VWF, TIE1,
ROBO4 and ECSCR have very high expression levels in
umbilical cord tissue (Table 3). These results strengthen
our finding that these genes have relatively high expres-
sion levels in vascular related tissues.
To further explore whether any of the EC-restricted
genes have specific expression in particular tissues, we
obtained the immunohistochemistry data for 61 out of
the 109 EC-restricted genes. The majority of the EC-
restricted genes demonstrate a ubiquitous expression in
different normal tissues (Additional File 3). A small sub-
set of the genes show a restricted expression pattern in
normal tissues. For example, VWF and ICAM2 are
enriched in soft tissues. BMX, one of the top ranked
endothelial restricted genes has preferential expression
in the epididymis. CLDN5 is preferentially expressed in
glandular cells of various body tissues. Interestingly,
about 85% of genes depict moderate to high levels of
expression in soft tissues.
Discussion
The results of our study demonstrate that of over 43,000
transcripts evaluated, only 152 appear to be highly
restricted to the endothelium. Several of the genes iden-
tified have previously been reported to exhibit an EC-
restricted expression pattern and have known functions
in ECs. Examples of these genes include angiopoietin-2,
von Willebrand’s Factor (vWF), EC nitric oxide synthase
(eNOS), and Pecam-1 (CD31). The pathways, and GO
categories of the identifie dg e n e ss u p p o r tar o l ef o r
these genes in vascular development, angiogenesis, and
EC function.
Although several of the EC-restricted genes have pre-
viously been shown to contribute to the regulation of
normal EC function, many others have not been charac-
terized as having a particular role in EC. The genes iden-
tified as being EC-restricted fall into several categories,
including proteins involved in transcriptional regulation,
cell adhesion, signal transduction, and intracellular traf-
ficking. The determination that these genes are enriched
in ECs may lead to future studies that define their speci-
fic role in regulating EC function.
The endothelium is known to play an important role in
a number of human diseases, and so it was not a surprise
that alterations in the expression of these genes are asso-
ciated with a number of cardiovascular disorders. Muta-
tions or alterations in the expression of several of the
genes listed have been shown to be associated with the
development of hypertension. For example, mutations in
the eNOS gene have been linked to patients with essen-
tial hypertension [21-23]. Similar associations have been
observed with mutations in the endothelin-1 gene
[24,25]. More recent studies point toward a link between
obesity and hypertension. There has been particular
interest at understanding the role of adipocytokines and
their receptors in the development of hypertension. Pre-
vious studies have suggested a causal link between leptin
levels in obese patients and the development of hyperten-
sion [26]. A more recently discovered adipocytokine, ape-
lin, is predominantly expressed in the ECs of the heart
and support a role for apelin in the development of
hypertension and cardiac hypertrophy [27].
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Page 13 of 18The endothelium is known to play an important para-
crine role with respect to cardiac function and develop-
ment. The TGFbeta family member cytokine, bone
morphogenetic protein-4 (BMP-4), is known to play an
important role during cardiac development [28]. Increased
expression of BMP-4 may similarly be reflective of a state
of EC dysfunction. Exposure of ECs to BMP-4 promotes
ROS generation [29]. BMP-4 expression is increased in EC
exposed to abnormal or unstable flow, compared to regions
of laminar shear flow [30]. Venous and microvessel ECs
Figure 6 Regulation analysis of EC-restricted genes. The list of the transcription factor binding sites that are enriched in 2 kb upstream to
100 bp downstream region. The enrichment in gene sets that are highly expressed in all endothelial cells and only microvascular EC is shown in
black and grey color respectively. The X-axis represents the transcription factors and Y-axis represents -log P value.
Figure 7 Regulation analysis of EC-restricted genes in term of MiRNA targets.T h el i s to ft h em i R N At h a ta r ee n r i c h e di n3 ’ UTR of EC
specific genes. The X-axis represents the miRNA’s and Y-axis represents -log P value. The miRNAs from the opposite standard of guided RNA
strand are marked with star (*).
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Page 14 of 18exposed to BMP-4 rapidly undergo apoptosis [31]. These
results suggest the possibility that BMP-4 could be a possi-
ble therapeutic target in the setting of heart failure to
improve or reverse EC dysfunction.
The functional and structural integrity of the central
nervous system depends on tightly controlled coupling
between neural activity and cerebral blood flow. This
requires the close interaction of neuronal cells and vas-
cular cells in a complex that is known as the neurovas-
cular unit. Recent experimental evidence suggest that
dysfunction of the neurovascular unit may be an early
event in Alzheimer’s disease. Studies in transgenic mice
overexpressing the amyloid precursor protein (APP)
exhibit abnormalities in blood flow in response to func-
tional hyperemia prior to the development of amyloid
plaques or vascular amyloid [32]. Administration of
soluble amyloid beta protein results in vasoconstriction,
EC dysfunction and a reduction in CBF. One of the
main mechanisms by which EC dysfunction occurs is
through inactivation or reduced function of EC nitric
oxide synthase (eNOS). Amyloid beta also induces the
production of reactive oxygen species, alteration in the
expression of tight junction proteins, and an increased
rate of EC apoptosis [33]. In the brain tissue samples
of patients with AD, we observed a significant increase
in the expression of selected adherens and tight junc-
tion proteins including VE-cadherin, claudin-5, and
connexin 37 (GJA4). Systemic administration of the
amyloid beta peptide 1-42 to rats is associated with
alterations in the expression and cellular localization of
several tight junction proteins [33]. Another EC-
restricted gene found to be significantly upregulated in
the AD brain tissue samples is von Willebrand’sF a c t o r
(vWF). Increased levels of vWF promote blood clotting.
Increased vWF has been found in heme-rich deposits
(HRDs) in patients with dementia [34]. HRDs are also
rich in fibrinogen, collagen IV, and red blood cells, and
are thought to be the residua of capillary bleeds, or
microhemorrhages. In patients with acute ischemic
stroke and vascular dementia, vWF levels have also
been shown to be increased [35].
Our analysis of potential transcription factors that
might be involved in regulating the expression of the
identified EC-restricted genes, based on conserved
binding sites in the regulatory regions of these genes
led to the identification of several classes of transcrip-
tion factors. Most of these transcription factors have
not previously been described as playing a major role
in the regulation of EC-restricted genes with some
exceptions. Members of the ETS and GATA transcrip-
tion factor families have been shown to regulate a
number of endothelial genes including vWF, VE-cad-
herin, and Tie1 [36-38]. Interestingly, several con-
served binding sites were identified only in the
regulatory regions of the microvascular ECs suggesting
that members of these transcription factor families
m a yp l a yau n i q u er o l ei nd e t e r m i n i n ge n d o t h e l i a l
gene expression in microvessels.
Over the past several years a role for microRNAs has
been demonstrated to play a role in regulating EC gene
expression, function, and in the process of angiogenesis.
Although most of the miRNAs we identified have not
been described for their roles in regulating EC-restricted
genes, a few have. For example, hsa-miR-296 has
recently been shown to play a regulatory role in angio-
genesis (39). Angiogenic factors can increase the
Table 2 List of significantly enriched miRNAs binding sites
microRNA Hits P-Value FDR Gene Symbol,
hsa-miR-432* 11 1.53E-04 0.035458796 PALMD,RAPGEF5,LOC90139,MYLK2, CETP,TIE1,GLCE,VWF,ROBO4,KIAA1274, PDE2A,
hsa-miR-188 10 7.60E-04 0.058786382 CDH5,EGFL7,CXorf36,,RNASE1,SEMA6B, ESAM,RGS3,ROBO4,HYAL2,
hsa-miR-132 6 6.39E-04 0.074133993 IL1RL1,CXorf36,LOC90139,SLC29A1, IPO11,LOC116441,
hsa-miR-331 9 0.002161 0.10028083 TXNRD2,LOC90139,FLJ22746,BCL6B, SEMA6B,ESAM,KIAA1274,TBX1,ICAM2,
hsa-miR-296 9 0.001918 0.111262412 ARHGEF15,CDH5,APLN,RNASE1, SEMA6B,ESAM,ROBO4,CGNL1,
hsa-miR-512-5p 8 0.00932 0.166330341 APLN,RAPGEF5,BCL6B,SLCO2A1, LOC400451,KDR,ROBO4,FLJ46061,
hsa-miR-503 8 0.008909 0.172244646 APLN,LOC90139,ESAM,MGC20262, VWF,ROBO4,ZDHHC14,HYAL2,
hsa-miR-518e 5 0.008905 0.187818163 LAMP3,NOTCH4,BCL6B,GLCE,SEMA6B,
hsa-miR-520a* 8 0.008722 0.202353355 EGFL7,FLJ10241,APLN,ABCA4, HSD17B2,SHANK3,ESAM,CGNL1,
hsa-miR-345 8 0.008564 0.220764545 FLJ10241,RAPGEF5,MYLK2,ADCY4, PLSCR4,GJA4,RGS3,PDE2A,
hsa-miR-490 8 0.008331 0.241605345 CDH5,ESAM,MGC20262,ROBO4, FLJ46061,MOV10L1,CGNL1,ICAM2,
hsa-miR-299-3p 5 0.007968 0.264095479 APLN,TNFRSF11A,TIE1, PECAM1,ROBO4,
hsa-miR-328 8 0.007307 0.282532121 EGFL7,CLDN5,CXorf36,LOC90139,SEMA6B, RGS3,ROBO4,KIAA1274,
hsa-miR-525 7 0.029061 0.293137643 EGFL7,FLJ10241,RAPGEF5,NOTCH4, FLJ22746,ESAM,FLJ46061,
hsa-miR-337 7 0.027316 0.301772827 RAPGEF5,FLJ22746,SHANK3, LOC400451,PLSCR4,KIAA1274,
The miRNAs that are expressed at relatively low level as compared to miRNA from opposite/guided standard are marked with star (*).
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Page 15 of 18expression of hsa-miR-296. Down regulation of hsa-
miR-296 in ECs inhibits angiogenic responses in cul-
tured ECs. Furthermore, inhibition of hsa-miR-296 with
antagomirs reduced angiogenesis in tumor xenografts in
vivo. Similarly, hsa-miR-328 has been implicated in the
regulation of CD44 [39]. CD44 regulates a wide variety
or processes including angiogenesis and inflammation.
T h ef a c tt h a to n l yas m a l ls u b s e to ft h em o r et h a n7 0 0
microRNAs has thus far been shown to regulate EC-
restricted genes or play a role in regulating EC function
suggests that several additional members, including
t h o s ew eh a v ei d e n t i f i e d ,m a yw e l la l s op l a yar o l ei n
regulating the expression of selected EC-restricted genes
or EC function.
We recognize that there are potential limitations of
our study. First, the study used expression-profiling data
based on RNA obtained from human tissues or cells.
Although several of the genes identified are known to
be vascular-specific, the newly identified genes will ulti-
mately need further validation as to the true extent of
their EC specificity, at the level of protein and/or RNA
both in cells and tissues, and to validate their EC-
restricted pattern within the identified tissues.
Conclusion
Our study validates the existence of a finite number of
endothelial-restricted genes most of which are ubiqui-
tously expressed. Several of these are restricted to cells
of microvascular origin. Although several of the genes
Figure 8 Relative normalized expression levels of EC-restricted
genes in normal tissues. The expression level is expressed as
relative percentage of expression in different tissues with red, yellow
and green color denoting higher, median and lower expression
levels respectively. The rows represent each gene and columns
represent each normal tissue type.
Table 3 Normalized Expression Level of top endothelial
restricted genes obtained from the Source database
Gene Symbol Rank Score Normalized Expression
MMRN1 11157.50625 Vascular (29.44%)
Umbilical cord (16.7%)
CLDN5 5933.421875 Adipose (66.3%)
VWF 4772.862931 Umbilical cord (43.9%)
BMX 4447.913846 Vascular (56.1%),
Umbilical cord (10.1%),
Ganglia (11.8%)
ANGPT2 1412.88625 Vascular (19.2%),
Umbilical cord (16.3%),
Placenta (12.5%)
GJA4 1284.435 Adipose (24.4%),
Placenta (10.8%),
Ganglia (9.3%)
CDH5 1115.751864 Vascular (19.6%),
Placenta (29.4%)
TIE1 1107.308411 Umbilical cord (16.0%),
Ganglia (22.2%)
ROBO4 975.358913 Umbilical cord (82.4%)
ECSCR 646.6127586 Umbilical cord (44.6%)
The relative expression level of the genes in different tissues is expression as
percentage. The gene expression data for generating the normalized
expression level was DbEST database of normal tissues at NCBI.
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Page 16 of 18are known to play important roles in endothelial func-
tion, the exact functional role of many others in
endothelial cells remains tob ed e f i n e d .W eh o p et h a t
our study provides an initial catalogue of EC-restricted
genes that can lead to further studies that either link
alterations in the expression of these genes to a variety
of human diseases via their role as biomarkers or are
ultimately shown to play a causal role in the pathogen-
esis of the particular human diseases.
Additional file 1: Nucleotide sequence of primers used for RT-PCR
to validate expression pattern of selected EC-restricted genes.
Additional file 2: Summary of miRNA Binding sites along with
target and reference sequences.
Additional file 3: Immunohistochemistry based expression level of
genes in different tissues. Rows represent the different tissues and
columns represent the different EC-restricted genes. The expression level
is shown in four color circle scheme i) Red represents strong expression
ii) Orange represents moderate expression, iii) Yellow represents weak
expression, iv) White represents no detectable expression and Black
represents no representative images. The data was obtained from human
protein atlas database.
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